Biofrontera AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biofrontera AG with three other
pharmaceutical manufacturers in Europe:
sales of 281.56 million Norwegian Kroner [US$31.21 million]
of which 52%
was Hexvix/Cysview Own Sales),
Malin Corporation Plc
(34.90 million Euros [US$41.25 million]
of which 100%
was pharmaceutical products,), and
based in FRANCE
(34.23 million Euros [US$40.46 million]
of which 57%
was Sale of Goods).
Biofrontera AG reported sales of 31.27 million Euro (US$36.96 million)
December of 2019.
increase of 48.1%
versus 2018, when the company's sales were 21.11 million Euro.
Sales at Biofrontera AG have increased during each of the previous five years
(and since 2014, sales have increased a total of 910%).